NCT05837260Recruiting
Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
A Multicentre Prospective Study Investigating the Utility of ctDNA as a Biomarker of Disease Burden, Genetic Heterogeneity and Tumour Evolution in Advanced Thyroid Cancer
Source: ClinicalTrials.gov · Last updated 9 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 19 Apr 2023
- Start date
- 23 Mar 2023
- Primary completion date
- 7 Feb 2027
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Diseases
- Thyroid cancer
- NCT number
- NCT05837260
What you commit to
- Study type: Observational
- Planned participants: 120
- From 23 Mar 2023 to the primary completion date, 7 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection
- Any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ)
Other
- Pregnancy
Who the study is looking for
- Age 18 years or older. (all cohorts)
- Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1)
- Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2)
- Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3)
- Patients with newly diagnosed anaplastic thyroid cancer (cohort 4)
- Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts)
- Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts)
- Ability to give informed consent for biological sample collection. (all cohorts)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Marsden NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.